Haleon (HLN) said Tuesday it has completed its acquisition of an additional 33% stake in its Chinese joint venture, Tianjin TSKF Pharmaceutical, from its partners Tianjin Pharmaceutical Group and Tianjin Pharmaceutical Da Ren Tang Group.
The total consideration was about 4.47 billion Chinese renminbi ($611.8 million), according to its regulatory filing. It expects the deal to be accretive to EPS.
Price: 9.58, Change: +0.07, Percent Change: +0.74
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments